The monarchE trial's primary overall survival (OS) analysis presented at ESMO 2025 confirms that 2 years of ...

I was 19 when I dragged myself — half-hearted and unimpressed — to the compulsory Breast Cancer Awareness seminar at Fatima Jinnah Women University in Rawalpindi. I was just a young undergraduate ...

A major European clinical research event in oncology gives a boost to antibody–drug conjugates, treatments that work like a Trojan horse, delivering chemotherapy to the interior of malignant cells ...

A newly developed antibody which restricts the growth of treatment-resistant breast cancers offers new hope for patients.

AI-driven nanomedicine advances enable personalized breast cancer treatments, combining precision, biomimetic nanocarriers, ...

These preclinical data underscore the potential of ORIC-944 to overcome resistance not only in prostate cancer but in other solid tumors and highlight that the therapeutic potential of PRC2 inhibition ...

Adding abemaciclib to standard endocrine therapy reduces the risk of death and recurrence in patients with breast cancer.